Nilotinib

Chronic Myeloid Leukemia Treatments

Chronic myeloid leukemia, also known as chronic myelogenous leukemia or CML, is a kind of leukemia that starts in the cells in the bone marrow that form blood, according to the American Cancer Society. CML cells accumulate in the body over time,...

Nilotinib Web Results

Nilotinib

Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor. This type of medicine is used in treatment of leukemia (specifically ...



Nilotinib - Wikipedia, The Free Encyclopedia

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved for the treatment of chronic ...



Complete Nilotinib Information From Drugs.com

Nilotinib professional patient advice. Specific and up to date information about Nilotinib.



TASIGNA Is Now Indicated For Patients Newly Diagnosed With Ph+

Tasigna (nilotinib) is a treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults resistant or intolerant to Glivec.



FDA Approval For Nilotinib - National Cancer Institute

Information from the FDA about the approval of nilotinib and the clinical trials that led to the approval.



Nilotinib - PubMed Health - National Center For Biotechnology ...

Warning. Nilotinib may cause QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death).



Nilotinib - National Cancer Institute - Comprehensive Cancer ...

This page contains brief information about nilotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical ...



CML (Chronic Myeloid Leukemia) Treatment: Find Out If Tasigna Is ...

Tasigna (nilotinib) 150-mg and 200-mg capsules from Novartis is a treatment for Ph+ Chronic Myeloid Leukemia in newly diagnosed adult patients in chronic phase or ...



What Is Nilotinib | About Nilitinib

Studies show nilotinib is 20 to 50 times stronger than imatinib. ... Chemists created nilotinib with the idea of improving the target specificity of an ...



Nilotinib - Clinical Cancer Research

Michael W. Deininger; Author's Affiliation: Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon



results by
powered by Bing